---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-021960"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:08:41.391870+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zai Lab Q2 2022 revenue $48.2M (+31% YoY); net loss narrows; efgartigimod BLA accepted in China

## Summary
- Total revenues $48.2M (Q2 2021: $36.9M); ZEJULA revenue $34.1M (+46% YoY). Net loss $137.9M vs $163.3M.
- Cash position $1.26B; NMPA accepted BLA for efgartigimod in generalized myasthenia gravis.
- Karuna's KarXT Phase 3 EMERGENT-2 met primary endpoint: 9.6-point PANSS reduction vs placebo (p<0.0001).
- Josh Smiley appointed COO effective Aug 1; John Diekman named Lead Independent Director.

## SEC filing metadata
- accession: 0001628280-22-021960
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828022021960/0001628280-22-021960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828022021960/zlab-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-021960
- JSON: https://secwatch.observer/filing/0001628280-22-021960.json
- Plain text: https://secwatch.observer/filing/0001628280-22-021960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.